Maynard-based Allegro Diagnostics has entered into a license agreement with Boston University and the University of Utah Foundation for a molecular platform that could help detect lung cancer at an early stage.
Financial terms of the deal were not disclosed. Allegro has developed a platform to detect molecular changes in the respiratory tract that occur when cancer is present.
The company is currently conducting a multi-year trial for BronchoGen, a lung-cancer detection system that would be the company’s first commercial product.
